Market Cap: $55.41B
BA
Bayer AG
BAYRY
OTC (Other OTC)USD
Market Cap: $55.41B
Bayer AG Poised to Benefit from U.S. Defense Production Act for Herbicides In a decisive move highlighting a shift towards strengthening domestic agricultural production, President Donald Trump signs…
U.S. DPA move on glyphosate and phosphorus places strategic spotlight on Bayer AG A presidential order invoking the Defense Production Act to boost domestic supplies of elemental phosphorus and glypho…
Bayer presses $10.5 billion plan to resolve Roundup cancer litigation Bayer AG is pushing a $10.5 billion settlement package to resolve current and future U.S. lawsuits alleging its Roundup weedkiller…
Bayer moves to cap Roundup litigation with $10.5 billion settlement package Bayer AG announces a proposed $10.5 billion package to resolve current and future U.S. lawsuits that allege its Roundup weed…
Supreme Court review could redefine Roundup liability for Bayer The U.S. Supreme Court is set to hear Monsanto Co. v. Durnell on April 27, a case that could reshape how liability for glyphosate‑based…
Supreme Court to resolve Roundup preemption fight The U.S. Supreme Court is agreeing to hear Monsanto Co. v. Durnell on April 27, setting up a high-stakes test of whether federal pesticide labeling la…
Bayer’s Roundup Appeal Moves to the Supreme Court Supreme Court Takes Up Roundup Liability Fight The U.S. Supreme Court on Feb. 11 announces it will hear Monsanto Co. v. Durnell on April 27, taking di…
Market turbulence tests Bayer’s commodity, currency and funding exposure What the market swing means for Bayer’s crop science and chemical costs Global equity volatility and swings in commodities are…
Market volatility touches commodity and energy markets Global risk swings are transmitting into commodity and energy markets, testing input-cost dynamics for large agrochemical and pharmaceutical firm…
Commodities shock tightens margins for Bayer’s crop and chemical operations Volatility in commodities and credit markets is putting renewed pressure on input costs and supply-chain financing for large…
Bayer AG Positioned for Legal Victory Amid Trade Tensions Bayer AG is currently experiencing a positive shift in its stock performance following the US Supreme Court's decision to hear its appeal conc…
Bayer AG's Legal Momentum in Roundup Litigation Amid Trade Tensions Bayer AG experiences a notable uptick in share prices as the US Supreme Court agrees to hear its appeal concerning the ongoing Round…
Bayer AG Secures Legal Momentum Amidst Trade Tensions In a significant legal development, Bayer AG experiences a notable increase in its stock value following the US Supreme Court's decision to hear t…
Bayer AG Advances Gene Therapy Efforts with FDA Acceptance for Pompe Disease Treatment Bayer AG's wholly owned subsidiary, AskBio Inc., marks a pivotal moment in gene therapy development with the rece…
Bayer AG Advances Gene Therapy for Pompe Disease with IND Acceptance Bayer AG's wholly owned subsidiary, AskBio Inc., celebrates a pivotal achievement with the acceptance of its Investigational New Dr…
Bayer AG Advances Gene Therapy for Pompe Disease with IND Acceptance Bayer AG's subsidiary, AskBio Inc., marks a significant achievement in the realm of gene therapy with the recent acceptance of its…
Bayer AG's Role in the Industrial Agriculture Debate: A Critical Examination Bayer AG stands at the crossroads of modern agricultural practices and the growing criticism surrounding industrial farming…
Bayer Partners with Cradle to Enhance Drug Development Through AI Bayer AG has entered into a strategic three-year collaboration with Cradle, a company renowned for its advancements in scientific AI s…
Bayer AG Expands AI Capabilities with Strategic Partnership Bayer AG has forged a significant three-year collaboration with Cradle, a company at the forefront of scientific AI software specializing in…
Bayer AG's Strategic Focus on siRNA Therapeutics Bayer AG is making significant strides in the field of small interfering RNA (siRNA) therapeutics, positioning itself as a leader in this rapidly evolv…
Bayer AG Advances Nucleic Acid Therapeutics: A Focus on siRNA Technology Bayer AG solidifies its position as a frontrunner in the biopharmaceutical industry through its commitment to developing small…
Bayer AG Faces Scrutiny Over Glyphosate Research Integrity In recent developments, Bayer AG contends with mounting scrutiny over the integrity of academic research related to its controversial herbici…
Bayer AG and IBM’s Game-Changing Partnership in Football Analytics Bayer AG, through its collaboration with IBM, is transforming the landscape of professional football analytics. The partnership focus…
Bayer Defends Roundup Amid Legal Challenges and Regulatory Scrutiny Bayer AG's CEO Bill Anderson stands firm in defending the safety profile of Roundup, a widely used herbicide that has come under int…
Bayer AG Advances Stroke Prevention with Promising Phase 3 Study Results Bayer AG announces significant findings from its Phase 3 OCEANIC-STROKE study, evaluating asundexian, an investigational oral F…